Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Tharimmune, Inc. on October 23, 2023. The filing details the voting outcomes for director elections, auditor ratification, equity incentive plans, and a proposed reverse stock split. A total of 10,937,815 shares were represented at the meeting, constituting a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Proposal 1 (Director Elections): Five nominees were elected to the Board of Directors. All received significant support, with "For" votes ranging from approximately 7.8 million to 8.4 million shares.
- Proposal 2 (Auditor Ratification): Stockholders approved the ratification of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 10,732,062 For, 203,030 Against, and 2,723 Abstain.
- Proposal 3 (Equity Incentive Plan): Stockholders approved the 2023 Omnibus Equity Incentive Plan. The vote was 8,129,962 For, 375,606 Against, and 2,470 Abstain.
- Proposal 4 (Reverse Stock Split Authority): Stockholders granted the Board discretionary authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50. The vote was 10,382,866 For, 544,784 Against, and 10,164 Abstain. Any such split must be completed no later than October 23, 2024.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard disclosure of the reverse stock split mechanics. The approval of the reverse stock split authority indicates a strategic move to potentially increase the per-share trading price, subject to Board discretion and regulatory approval.
Investor Verification Checklist
- Verify the final implementation date and specific ratio of the reverse stock split, as the Board now has discretion to act within the 1-for-2 to 1-for-50 range.
- Confirm the composition of the newly elected Board of Directors and their tenure terms.
- Review the terms of the newly approved 2023 Omnibus Equity Incentive Plan for potential dilution impacts.
- Monitor future filings for the actual execution of the reverse stock split before the October 23, 2024 deadline.